Primogene develops and operates an enzymatic biomanufacturing platform to produce structurally complex biomolecules identical to their natural counterparts, including HMOs like DSLNT and difucosyllacto‑N‑tetraose I. The company manages the full value chain—enzyme development and production, biotransformation, and downstream processing—at its facility in Leipzig. It emphasizes enzymatic processes to overcome limitations of fermentation approaches and to enable scalable, cost‑efficient production of complex ingredients. Primogene holds an IP portfolio across several product categories and has established commercial partnerships in the personal care sector while pharmaceutical raw materials are in advanced customer evaluation. Founded in 2023, the company is expanding production capacity, growing its team, and seeking joint development partners among infant formula and functional food manufacturers. It is also collaborating with Fraunhofer IZI on infection‑prevention research and working with neonatal intensive care units to monitor HMO concentrations in breast milk.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026